Back

Efficacy and safety of PCSK9 inhibitors in lipid control in a follow-up at 6 months.

19 April 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Lipids Lipids EAPC Premium Access EuroPrevent 2018

About the speaker

Photo
Doctor Alfredo Chauca Tapia

University Hospital of Bellvitge, Barcelona (Spain)

9 More presentations in this session

Presentation thumbnail
Lipids - Poster discussant:
Presentation thumbnail
Improvement of lipid profile post cardiac rehabilitation according to the patient's level of risk in a tertiary hospital
Doctor A. Chauca Tapia (Barcelona, ES)
Presentation thumbnail
Efficacy of the PCSK9 inhibitors evolocumab/alirozumab in the reduction of LDL and Lp (a) in patients with familial hypercholesterolemia/manifest atherosclerosis in a real world setting
Mr M. Poudel (Bielefeld, DE)
Abstract Slides
Presentation thumbnail
Anti-PCSK9 in everyday clinical practice
Doctor R. Cadenas Chamorro (Madrid, ES)
Abstract Slides
Presentation thumbnail
Evaluation of LDL cholesterol level in patients with coronary artery disese after cardiac rehabilitation
Professor N. Mouine (Rabat, MA)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Lipids

The Event

Event poster

EuroPrevent 2018

19 April - 21 April 2018

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources